Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
Progress in the treatment of Hodgkin lymphoma are among the most significant achievements of oncology of our age. Nevertheless, an early relapse or refractory course of the disease account for approximately 15–20% of cases. It was this category of patients, in which the target drug brentuximab vedot...
| 出版年: | Медицинский совет |
|---|---|
| 第一著者: | |
| フォーマット: | 論文 |
| 言語: | ロシア語 |
| 出版事項: |
Remedium Group LLC
2018-11-01
|
| 主題: | |
| オンライン･アクセス: | https://www.med-sovet.pro/jour/article/view/2755 |